

The Innate Immune System of the Perinatal Lung and Responses to Respiratory Syncytial Virus Infection

Rachel J. Derscheid¹, Mark R. Ackermann^{1*}

¹ Department of Veterinary Pathology, 2738 College of Veterinary Medicine, Iowa State University, Ames, Iowa 50011, USA; rdersch@iastate.edu; mackerma@iastate.edu

* Author to which correspondence should be addressed; mackerma@iastate.edu; Tel.: 515-294-3647; Fax: 515-294-5423

ABSTRACT:

The response of the preterm and newborn lung to airborne pathogens, particles and other insults is initially dependent upon innate immune responses since adaptive responses may not fully mature and require weeks for sufficient responses to antigenic stimuli. Foreign material and microbial agents trigger soluble, cell surface and cytoplasmic receptors which activate signaling cascades that invoke release of surfactant proteins, defensins, interferons, lactoferrin, oxidative products and other innate immune substances that have antimicrobial activity which can also influence adaptive responses. For viral infections such as respiratory syncytial virus (RSV) the pulmonary innate immune responses has an essential role in defense as there are no fully effective vaccines or therapies for RSV infections of humans and reinfections are common. Understanding the innate immune response by the preterm and newborn lung may lead to preventive strategies and more effective therapeutic regimens.

Key words: innate immunity, lung, respiratory syncytial virus (RSV), pneumonia

INTRODUCTION

With the first breath after birth the lung is exposed to a wide variety of airborne substances and microbial agents. Despite this, most newborns do not develop extensive pulmonary inflammatory/immune responses which would impair airflow and gaseous exchange. This is due, at least in part, to the innate immune system's clearance of particulate matter and discrete handling of other substances and microbial agents. The response to pathogens and foreign material, vapors, fluids, aerosols, mists, and other substance by the perinatal lung is especially dependent upon innate immune responses since adaptive immune responses are not fully mature and can require weeks for sufficient responses to antigenic stimuli. The innate immune system of the lung includes the mucociliary apparatus, air-surface liquid and its contents, epithelia, serum products, dendritic cells and other leukocytes (**Fig. 1**). Foreign material and microbial agents trigger soluble, cell surface and cytoplasmic receptors which activate signaling cascades that trigger release of surfactant proteins, defensins, interferons, lactoferrin, oxidative products and other innate immune substances that have antimicrobial activity and can also invoke adaptive responses. For viral infections such as respiratory syncytial virus (RSV), innate immune responses are increasingly appreciated for their role in reducing disease severity. RSV is a common respiratory pathogen world-wide and can cause severe bronchiolitis and respiratory disease resulting in hospitalization in infants (especially preterm), immunosuppressed individuals and the elderly (21, 95). Each of these categories of people has less than optimal adaptive immune responses and thus innate immune responses become even more vital since there are no approved vaccines or fully satisfactory therapies. Vaccine development for RSV in humans has been hindered by deaths that occurred in RSV infected infants previously vaccinated with a formalin-inactivated vaccine in a trial in the 1960's (21). Although RSV is a ubiquitous virus and most all women have circulating antibodies, preterm infants may have

a limited amount maternal antibody because the shortened gestational time of an infant born preterm reduces the amount of time for transplacental passage of maternal immunoglobulin. Therefore, some preterm infants have limited maternal antibody, their immune system has not ever been exposed to RSV or many other antigens, and their adaptive immune system is not fully mature. Such individuals are heavily dependent upon their innate immune response for protection against severe RSV infection. Also, RSV and other viruses such as influenza, infect bronchiolar epithelial cells and once infected become inflamed impairing airflow and thus the gaseous exchange function of the lung. Reducing bronchiolar epithelial cell infection is vital, especially for RSV since there are no fully satisfactory therapies or approved vaccines. Cattle and sheep are also susceptible to RSV infections especially during times of stress as can occur with shipping, weaning, overcrowding, poor management, and improper environmental and housing conditions. Such stress can also impair adaptive and innate immune responses leading to increased susceptibility. Our laboratory has developed a lamb model of RSV infection that closely mimics key features of RSV infection in newborn infants (23). This review addresses key features of the respiratory innate immune system of the perinatal lung comparing newborn and adult. It highlights responses to one specific virus, RSV, which is a serious and common pathogen of infants, cattle, and sheep.

Components of the innate immune system and responses to RSV

The newborn lung is challenged by foreign material and airborne stimuli that can invoke cellular responses. The molecular machinery of receptor recognition, signaling, activation or suppression of transcription factors, mRNA transcription, translation, protein translocation and activity is triggered to a newly experienced level by the various lung cell types while the

lung itself transitions to its primary function: gaseous exchanges. This dynamic activity is even more complicated in newborns that are preterm or premature and also in those with physiologic stress, inherited disorders or pathologic conditions. Investigations of the perinatal lung of human infants have limitations in monitoring and measuring cytokine, chemokine, cellular, and humoral responses, particularly localized responses. The methods used must generally be minimally invasive, which limits the amount and type of data that can be collected from the pulmonary response to microbial agents. Additionally, variations in disease diagnosis as well as method of sample collection create difficulties in comparisons between studies. Despite these challenges, much has been learned from human subjects and while knowledge gaps are addressed in a wide variety of animal models.

In perinatal, maturing and adult lungs, the initial diseases or stresses caused by viruses, other microbial agents and their products, antigens, allergens, foreign material, vapors and substances arriving in the lung via the vasculature have an acute onset and typically a fairly short duration, although there can be protracted or recurring symptoms, depending on the inciting stimulus. Minimal or mild exposure of these insults is handled every moment by the pulmonary tract of healthy individuals without incident. Because airflow and gaseous exchange are optimal in non-inflamed lung, it is beneficial for the inflammatory response to be as minimal and rapid as possible. Mucociliary clearance and physiologic activity of innate immune products secreted onto the air-surface liquid (ASL) are of special importance in this regard to avoid/reduce epithelial cell damage, bronchoconstriction, vascular leakage and an overt inflammatory or adaptive response. There is a range of responses by individuals and severity of disease, with some individuals at increased risk due to altered lung structure or function and potentially a reduced ability to develop an adaptive response compared to others that typically experience mild disease. Such variations between

individuals range from differences in gross structure (e.g., diameter of the nasal meatus or length of the trachea), epithelia (e.g., numbers and distribution of goblet cells); immune (e.g., distribution of dendritic cells or mast cells) and genetic (e.g., single nucleotide polymorphisms and gene copy number of cytochrome P450 isoenzymes, defensins, or surfactant proteins A and D).

The physical innate barriers of mucous production, mucociliary elevator apparatus, submucosal gland secretions, and complex branching of the respiratory tree must initially be overcome by microbial agents such as RSV to reach bronchiolar epithelium and respiratory airways where the virus establishes infection and replicates (98). Once a virus, microbial product, allergen, antigen or foreign material deposits onto the mucosal surface of the respiratory airways, it comes in contact with the mucosal secretions and the air-surface liquid (ASL).

In trachea, bronchi, and to some degree the bronchioles, the mucosal secretory layer of these airways is composed of periciliary sol and gel layers of the mucociliary apparatus formed from secretions from goblet cells, submucosal glands, and respiratory epithelial cells. The periciliary sol layer contains water that accumulates with chloride released from nearby epithelial cells, submucosal glands, and serous cells. The sol layer contains tethered mucins that form a “brush” layer on which the overlying mucus layer sits (18). The sol (also termed “ciliary brush”) layer allows cilia beat activity maintained in the proper pH and the amount of water in the sol layer is regulated by sodium (Na^+) resorption by epithelial Na^+ channels (ENaC). With dehydration, the sol (ciliary brush) layer becomes thinner and the tethered mucins aggregate both of which decrease ciliary beat. Certain other conditions such as cystic fibrosis and chronic obstructive pulmonary disease (COPD) can alter the consistency of the sol (ciliary brush) layer (18). The gel layer is composed of mucin

glycoproteins encoded by 22 *MUC* genes of which 16 have been identified in the human lung including MUC1, MUC2, MUC4, MUC5AC, MUC5B, MUC7, MUC8, MUC11, MUC13, MUC15, MUC16, MUC18, MUC19, MUC20, MUC21, MUC22. These proteins are linked to oligosaccharides and localize along the apical epithelial surface, some in a secreted form, others tethered to the cell membrane. Some, such as MUC5AC are secreted by goblet cells, while others, such as MUC5B are secreted from mucous cells and submucosal glands (64). MUC1 is membrane-tethered and expressed by lung epithelial cells, including type II cells (64), and has anti-inflammatory properties through inhibition of Toll-like receptor (TLR) signaling. With RSV infection, mucin production is regulated by TLR7, IL-17 and IL-23 (85). Expression of *MUC* genes can be altered by acute disease conditions such as preterm birth, dehydration, heat, smoke and particulate matter and chronic conditions such as allergic conditions, chronic obstructive pulmonary disease (COPD), recurrent airway obstruction (horses), toxins (e.g., bleomycin), chronic infections, cystic fibrosis, and primary or metastatic neoplasia (18, 64).

Ciliary beat moves the pericellular ASL in an anterior direction in healthy individuals and various rates which can be measured. Certain disease conditions, such as primary ciliary dyskinesia (immotile ciliary syndrome; Kartagener Syndrome), exposure to certain toxins (e.g., ethanol, cigarette smoke), infectious agents (e.g., *Mycoplasma* sp.) can drastically reduce ciliary activity and thus impair physical clearance of the materials trapped within the ASL. Other conditions, such as cystic fibrosis and severe dehydration alter the hydration level of the ASL resulting in increased viscosity and a thick, mucinous layer that is not adequately propelled in an anterior direction by the cilia (18).

Submucosal glands are present in the nasal cavity, trachea, and bronchi of humans, cattle, sheep, and pigs; however, in rodents submucosal glands are limited to the upper airways

(17, 64). Submucosal glands work in concert with respiratory epithelium to create an oxidative host defense system at the mucosal surface through production of secretory products that contribute to the mucosal gel and sol layers. Submucosal glands produce lactoperoxidase (LPO) which works in concert with other enzymes and molecules to form oxidative radicals within the ASL that contribute to antimicrobial defense. Airway epithelia adjacent to submucosal glands transport thiocyanate (SCN^-) to the epithelial surface and also produce hydrogen peroxide (H_2O_2) via intracellular dual oxidases (Duox) (22, 38, 142). LPO secreted by the submucosal glands onto the air-surface liquid catalyzes the conversion of H_2O_2 and SCN^- to oxythiocyanate (OSCN^-). The Duox/LPO system has microbicidal activity against multiple bacteria and viruses (22, 142). *In vitro* assays that substitute I^- for SCN^- in the LPO/Duox system have shown killing of RSV to the same level of bleach (37). Submucosal glands also secrete lactoferrin and lysozyme, two important factors in innate immunity, especially in the air-surface liquid ASL. Lactoferrin is an antimicrobial glycoprotein that not only binds pathogens directly, but acts as an immunomodulatory protein and bridges the innate-adaptive immunity crossover (73-75). Pneumocytes (alveolar type I cells) make minor contributions to the amount of lactoferrin and lysozyme present in ASL (27).

Tracheal, bronchial, and bronchiolar epithelial cells have an active role in immunity through the secretion of immunomodulatory compounds with innate antimicrobial activity, as well as secretion of cytokines and chemokines upon infection to recruit immune cells. Epithelial cells produce innate immune molecules with anti-RSV activity. Surfactant proteins A and D (SP-A and SP-D, respectively) are collectins that bind pathogens with the globular head region (mannose-binding C-type lectin) and signal with the collagen-like tail. Both SP-A and SP-D are produced and secreted into the airway by primarily type II epithelial cells with a lesser contribution by Clara cells. SP-A and SP-D are reduced in infants with RSV disease

that require ventilator assistance (62). In cultured cell studies, SP-A and SP-D mRNA expression is increased by RSV infection, but protein expression is decreased, putatively through decreased translational efficiency (16). SP-A binds mannose residues of microbial agents and to RSV F protein resulting in increased viral clearance (77, 117). SP-D enhances phagocytosis and clearance of RSV in a mouse model (76). Both SP-A and SP-D enhance RSV elimination (43). Genetic polymorphisms in SP-A or SP-D are associated with altered severity of RSV infection (3, 28, 69), underscoring the essential role of these collectins in anti-viral defense. Expression of SP-A and SP-D increases throughout fetal lung development in lambs (91, 133). RSV infection of lambs enhances expression of SP-A and SP-D and is associated with viral clearance (44, 61, 101, 102). Drugs, such as ethanol exposure *in utero*, reduce SP-A production in lungs of newborn and may explain, at least in part, why ethanol consumption by pregnant mothers is a risk factor for severe RSV disease (72).

There are many other proteins produced by respiratory epithelia that contribute to innate defense; however, often their activity and function is not completely defined (**Tables 1, 2**). Secretory leukocyte protease inhibitor (SLPI) is a serine antiprotease and as such protects the lung against enzymes released from neutrophils and other leukocytes but SLPI also has antimicrobial and antiviral activity (118, 139). Palate, lung and nasal epithelium (PLUNC) proteins are produced at high levels by upper respiratory epithelia and have homology to lipopolysaccharide (LPS) binding protein and bacterial/permeability-increasing protein (BPI) suggesting a role for PLUNC in LPS binding (118, 139). BPI protein can bind LPS and also has bactericidal activity against Gram-negative bacteria. Ribonuclease 7 (RNase 7) has been identified in skin epithelia (and thus, is likely also present in the stratified squamous epithelium of the anterior nasal meatus) and has potent bactericidal activity. Lipocalin (also known as neutrophil gelatinase-associated lipocalin) can bind bacterial siderophores (118).

Beta defensins are antimicrobial cationic peptides also produced by respiratory epithelium, including pneumocytes and submucosal glands (95, 118, 139) of many species, including all domestic animals, rodents, and avian species. The beta defensins have direct antimicrobial activity against a wide-variety of microbial pathogens, and also have numerous other functions including leukocyte and dendritic cell chemotaxis, epithelial proliferation, mast cell degranulation, and immunomodulatory activity. Human beta defensins (HBD) 1-4 are produced in the respiratory tract. HBD-1 is constitutively expressed while HBD2-4 are inducible (52). *In vitro* infection of lung epithelia induces HBD-2 production by TNF- α via a nuclear factor $\kappa\beta$ (NF- $\kappa\beta$)-dependent mechanism. Secreted HBD-2 then disrupts the viral envelope, interfering with viral entry into host cells (65). Alpha defensins are produced by neutrophils and enterocytes, including Paneth cells, and theta defensins are present in some non-human primates but are a pseudogene in humans. Similar to the beta defensins, the human cathelicidin LL37 is a cationic antimicrobial peptide (139). LL37 is stored in neutrophils and produced by other leukocytes as well as respiratory epithelium at a low level. LL37 can be up-regulated in disease and plays a role in direct microbial killing as well as in immunomodulation and apoptotic signaling (8, 13, 81, 139). Sheep produce a cathelicidin, SMAP29 which has potent anti-bacterial activity and sheep also express sheep beta defensin-1 (SBD-1) which increases with paramyxoviral infection (RSV is a paramyxovirus) and is associated with viral clearance (15).

Clara cells are non-ciliated bronchiolar epithelial cells with multiple roles in the airways. Clara cells biometabolize xenobiotics (19), secrete immunomodulatory substances (128), and act as progenitor cells (11). Just as type II pneumocytes serve as a proliferation pool to replace dead and damaged type I pneumocytes, Clara cells act as a progenitor for type II cells, forming a proliferation pool that is vulnerable to exhaustion, especially in neonates (123, 124), but also in chronic smokers (chronic toxin exposure) (14). Further, damage to or

dysfunction of Clara cells creates a proinflammatory environment due to the loss of their immunomodulatory secretions (29). In their immunomodulatory capacity, Clara cells secrete a unique protein: Clara cell secretory protein (CC10), also known as CCSP, CC16, secretoglobin, and uteroglobin. CC10 expression is increased throughout ontogeny (**Fig. 2**) and CC10 levels in BALF and serum during acute injury such as smoke inhalation or application of pneumotoxicants (naphthalene, 4-ipomeanol), but decreased in chronic or dysplastic airway dysfunction, such as asthma, COPD, or bronchopulmonary dysplasia (BPD) (112). Infants that developed BPD had lower levels of CC10 at birth than age-matched infants that did not develop BPD (112). Gene knockout studies performed in mice have shown increased inflammation and viral persistence in CC10-deficient mice when challenged with RSV; restoration of CC10 abrogated these effects (141). Amniotic levels of CC10 during mid-trimester were significantly higher in women who had preterm premature rupture of membranes compared to women who did not, and this elevation of CC10 could be in response to a proinflammatory event (106). While CC10 is the most studied secretion of Clara cells, Clara cells also produce SP-A and SP-D (100, 128). Clara cell cytochrome P450 enzymes such as CYP1A1 and CYP1A2 detoxify inhaled compounds and compounds entering the lung hematogenously. This is beneficial for some toxins; however, a toxic metabolite, 3-methylindolamine is a toxic metabolite formed by Clara cell metabolism of 3-methyl indole.

Type II cells of lung increase in number and distribution and also differentiate progressively in developing ovine fetal lung (17, 89, 91) and lungs of other animals. Type II cells proliferate to replace themselves and also differentiate into type I cells that line pulmonary alveoli. Type I cells produce surfactant, surfactant proteins A, B, C, and D, and also a myriad of innate immune products including defensins, cathelicidins, lactoferrin and also other inflammatory mediators such chemokines, interferons, and cytokines. Once infected

with RSV, type II cells of term lambs have increased expression of SP-A, SP-D and SBD-1; expression of these genes is reduced in RSV infected type II cells of preterm lambs and may, in part, explain the increased susceptibility and disease severity of preterm lambs and infants to RSV infection (61).

Proteoglycans of the extracellular matrix can also regulate pulmonary inflammation and the innate immune response. Proteoglycans consist of a protein backbone attached to a glycosaminoglycan (GAG) side chain. In the lung, GAGs include: hyaluronan (14%), chondroitin sulfate/dermatan sulfate (31%), heparin sulfate (40-60%)/heparin (5%) and keratan sulfate (<2%) (42). In the lung, the three families of extracellular matrix proteoglycans include large aggregating chondroitin sulfate proteoglycans (CSPG), small leucine-rich CSPGs, and heparan sulfate proteoglycans (HSPG). Perlecan, a HSPG is present in the basal lamina; versican and decorin (CSPGs) are present in interstitial spaces; while syndecans are membrane proteoglycans. These proteoglycans and GAGs bind to numerous cytokines, chemokines and growth factors sequestering the molecules in a latent, inactive state. These include CXC chemokines (CXCL1-4, CXCL8, CXCL10, CXCL12), CC chemokines (CCL2-5, CCL11), proinflammatory cytokines (IL-1 α and β , IL-2, IL-5, IL-6, IL-7, IL-12, TNF α , IFN γ), anti-inflammatory cytokines (IL-4, IL-10), and growth factors (fibroblast growth factors, vascular endothelial growth factor (VEGF), GM-CSF, and TGF β) (42). With inflammation and release of enzymes such as many of the matrix metalloproteinases, these inflammatory mediators can be released and become active modifying the inflammatory response, including leukocyte adhesion molecules and regulating both the innate and adaptive immune responses.

Further triggering of innate immune responses by RSV

If a virus such as RSV, another microbial agent or its product, an allergen or foreign material surpass the ASL and its contents, they can come in contact with the apical surface of epithelial cells of the lower airway (98). Once epithelial cells are infected and damaged by RSV, the blood-gas exchange is compromised due to cell degeneration, altered cell physiologic activity, and altered airflow through the airways due to intraluminal accumulation of necrotic cell debris, mucin, vascular fluid, and airway constriction. Infected epithelial cells are not passively dependent upon rescue by leukocytes, but the epithelial cells themselves have an active role in modulating the immune response as well as the release of anti-RSV compounds such as SP-A and inflammatory mediators and interferons that prevent viral replication. Such responses by epithelial cells are initially triggered by activation of pattern recognition receptors (PRRs), many of which are Toll-like receptors (TLRs). TLRs are highly conserved molecules that recognize pathogen-associated molecular patterns (PAMPs) common to many general groups of pathogens and classes of microbes. PRRs activated by RSV include TLR-4 (47, 64), TLR-2 (96), TLR-6, TLR-3, and retinoic acid-inducible gene I-like receptor (RIG-I) (83).

TLR-4 is a cell-surface molecule associated with CD14 that recognizes lipopolysaccharide (LPS) from Gram-negative bacteria and lipoteichoic acid from Gram-positive bacteria, as well as the F protein of RSV and other PRRs (39, 51, 68, 95). The F protein of RSV activates TLR4 through binding of MD-2 protein and this can be inhibited by Lipid A analog antagonists (111). Binding of the TLR-4/CD14 complex activates NF- κ B, eventually leading to secretion of IL-8, IL-10, IL-6, as well as increased expression of TLR-4 on epithelial cells (39, 68). There is scientific dispute over the impact of two TLR-4 single nucleotide polymorphisms (SNPs) in regards to RSV disease severity. Multiple studies found that a single SNP or a haplotype with two SNPs in the TLR-4 gene is associated with increased susceptibility to symptomatic RSV infection and premature birth (7, 109), while other studies

had contrary findings (26, 84, 105). Two dissenting articles examined a single SNP as opposed to the two-SNP haplotype. The third looked at immune response to RSV in 7-9 year olds' peripheral blood monocytes, as opposed to comparing epidemiologic RSV disease to the haplotype.

TLR-2 and TLR-6 form a cell-surface heterodimer (95). Binding of TLR-2 activates NF- κ B through a MyD88-dependent pathway, initiating production of interleukin 1-beta (IL-1 β) (119). Studies in knockout mice demonstrate TLR-2 and -6 signaling in leukocytes that stimulates an immune response to RSV (96).

TLR-3 is an intracellular TLR, present on the endosomal surface and recognizing dsRNA (95). RSV is a single stranded RNA virus, but in vitro studies have demonstrated that TLR-3 is activated during replication (pairing of template and daughter strands) and leads to increased CCL-5 (Regulated on Activation Normal T cells Expressed and Secreted (RANTES)) production (116). Downstream signaling typically leads to interferon alpha and beta (IFN α and IFN β) transcription. In lambs, TLR 3, 4, 7, and 8 are differentially expressed during fetal development (133).

RIG-I is an intracellular helicase that binds noncapped 5' triphosphated RNAs and subsequently activates interferon regulatory factors 3 and 7 (IRF3 and IRF7) which are transcription factors for IFN α and IFN β (95). Recently, nucleolin has been shown to be an important cellular receptor for RSV (136) F protein. After RSV enters lung epithelial cells, RIG-I is activated and upregulates CCL-5 and interferon-inducible protein (IP10) in addition to IFN- β (83). Melanoma differentiation associated gene-5 (MDA-5) is also a helicase that recognizes ds RNA released from some viruses. Both RIG-I and MDA-5 activated NF-kappa B, IRF-3 and -7 via mitochondrial antiviral signaling adaptor (MAVS), interferon beta promoter stimulator (IPS-1), virus-inducing signaling adaptor, and Cardif. Nucleotide-

binding domain, leucine-rich repeat (NOD)-like receptors can also detect viral, bacterial and other pathogens that enter the cytoplasm through the leucine-rich repeat domains. Over 20 NOD-like receptors have been identified. Some, such as NALP3, IPAF, and NALP1 activate the inflammasome in macrophages and other cell types resulting in caspase 1 activation of IL-1 beta and IL-18. Endogenous molecules such as heat shock proteins 60 and 70, urates, and adenosine activate epithelial cells, leukocytes, endothelial cells and other cell types in the lung. These endogenous substances are termed danger-associated molecular patterns (DAMPs) or alarmins. DAMPs activate inflammatory transcription factors; however, their signaling is modulated by simultaneous binding to CD24, which interacts with Siglec, a regulator of NF-kappa B.

Many viral PRRs describe induce upregulation of type I interferons, IFN- α and IFN- β . Many cell types in lung produce Type I interferons but plasmacytoid dendritic cells (pDCs; CD123+, CD303+, CD304+), which are present in lung, produce large amounts of IFN- α and lesser amounts of IFN- β after stimulation. Type I interferons reduce viral replication in cells, typically through JAK-STAT pathways, as well as by upregulating MHC I, thereby indirectly promoting the killing of virus-infected cells (48, 49, 67, 95); also by production of downstream IFN products such as protein kinase R that disrupts viral translation (107), 2',5'-oligoadenylate synthetase 1 (OAS1) that activates an RNase L to cleave viral RNA (67), ISGylation that inhibits viral replication (49), and MxA protein that binds viral nucleoprotein to prevent replication and transcription (48). Unlike other myxoviruses, RSV is resistant to MxA protein, although there are increased levels of MxA in peripheral blood of RSV-infected children (6, 20, 48). RSV's nonstructural proteins NS1 and NS2 disrupt interferons through IFN regulatory factor-3 (IRF-3). NS1 protein inhibits IFN transcription and NS2 disrupts IFN signaling in the target cell (135). A similar disruption of type I interferons by NS1 and NS2 working in concert at multiple points in the IFN pathway occurs in bovine RSV infection

(123). Since two of the 11 proteins of RSV aim to disable the interferon system, there may be therapeutic potential in counteracting the action of NS1 and NS2 to allow the immune system to better control RSV. RSV infection also decreases IFN β (as well as IL-10 and TGF- β) in term lambs (131). Type III interferons (interferon λ (lambda)) have been described and include IFN λ 1, 2, and 3 (also termed IL-29, IL-28A, and IL-28B, respectively). These interferons signal through IL-10R2 and IFNLR1; however, their function is still being fully elucidated.

Interferon gamma (IFN- γ) is a type II interferon and considered a Th1 cytokine, primarily produced by CD4+ T cells to activate macrophages, but in early RSV infection it is produced by natural killer (NK) cells, dendritic cells, and macrophages (95). TGF- β and IL-10 regulate IFN- γ by reducing IFN- γ expression and functional activity (95). Such reductions in IFN- γ expression affect viral infection since IFN- γ inhibits viral replication and increases MHC I and MHC II cell surface expression as well as increasing transcription of MHC I-associated peptides involved in antigen processing. Also, stimulation of macrophages by IFN- γ induces secretion of IL-1, IL-6, IL-8, and TNF- α (41). IFN- γ has been associated with increased CC10 protein and there is evidence of its involvement in regulation at the transcriptional level (113). Low IFN- γ in nasopharyngeal secretions has been associated with increased disease severity in RSV-infected infants (127). This may indicate a skewing toward a Th2-type response as stimulation of immature lung macrophages with IFN- γ reduced RSV titers in mice (31). IFN- γ is increased in term lambs infected with RSV and yet further increased in preterm lambs (over that of term lambs) (131, 132).

IL-1 β , IL-6 and TNF- α are proinflammatory cytokines produced by macrophages and epithelial cells that act to increase acute phase protein production from the liver, recruit neutrophils, and activate complement. A direct relationship has been demonstrated

between IL-1 β levels in pharyngeal secretions and severity of RSV disease (82). Infection of healthy adults' dendritic cells with RSV stimulates IL-1 β production and secretion, as well as the proinflammatory cytokines TNF- α and IL-6 (45). And high levels of TNF- α and IL-1 β are present in infants with RSV bronchiolitis (46, 88). TNF- α levels are increased in preterm lambs infected with RSV compared to term lambs (131).

Interleukin 8 (IL-8; CXCL-8), is a chemoattractant for neutrophils, basophils, and T cells that is secreted by monocytes, macrophages, fibroblasts, keratinocytes, and endothelial cells (93). IL-8 is increased in nasal wash secretions of infants 1-6 months old infected with RSV, and this increase is more pronounced in those with more severe disease (71). In the same study IL-8 levels were correlated with an increased required duration of supplemental oxygen as well as higher peak fractional inspired oxygen (71). In a study comparing term to preterm infants that experienced RSV infection before six months of age a similar correlation between clinical severity score and IL-8 was found, but not in preterm infants (14). This highlights the complexity of understanding how the immune response contributes to disease in infants. As previously mentioned, signaling through TLR-4 via NF- κ B is one mechanism leading to increased IL-8 (68). IL-8 is increased significantly also in lambs infected with RSV and likely contributes to the neutrophil infiltration into bronchioles of RSV-infected lambs and infants (131, 132).

Interleukin 10 (IL-10) is primarily produced by leukocytes, particularly monocytes, and overall has a dampening effect on cellular recruitment through downregulation of class II MHC molecules and downregulation of Th1 cytokine production (95). IL-10 is increased in nasal wash secretions of infants during RSV infection (94). Intriguingly, elevated IL-10 during acute RSV infection is associated with post-bronchiolitis wheeze (126). Heterozygosity of a SNP in the IL-10 gene was associated with a decreased incidence of

severe RSV, but not associated with any difference in the incidence of post-bronchiolitis wheeze (56, 126). IL-10 expression is decreased in term lambs infected with RSV (132).

TGF- β has a mixed effect on the immune response, activating neutrophils and typically inhibiting macrophage activation, although TGF- β does have the ability to activate or deactivate macrophages and monocytes depending on the rest of the cytokine milieu (5, 95). TGF- β is produced by NK cells and macrophages in innate immunity as well as T and B cells as part of the adaptive immune response (54, 134, 140). Proliferation and differentiation of CD4⁺ T cells is blocked by TGF- β , which may be associated with a general dysregulation of Th1/Th2 response in infants (138). TGF- β also plays a role in immunoglobulin production and class switching (134). With RSV infection, TGF- β expression is decreased in term lambs (132).

Macrophage inflammatory protein-1 (MIP) is a 4 member family of CC chemokines: MIP-1 α (CCL3), MIP-1 β (CCL4), MIP-1 δ (CCL9/10), MIP-1 γ (CCL15) (89). MIPs are expressed by lymphocytes, monocytes or macrophages, and epithelial cells and are generally proinflammatory, recruiting macrophages (89). MIP-1 α and MIP-1 β are the most thoroughly studied and well-characterized of the MIPs. Murine and *in vitro* studies show that MIP-1 α expression is increased in RSV infection (12, 25, 47, 103). MIP1- α was increased in the nasopharyngeal secretions of infants with severe bronchiolitis (40) and also increased in preterm lambs infected with RSV (131).

Monocyte chemotactic protein (MCP-1/CCL-2) is produced by epithelial cells and functions as a chemoattractant for monocytes, eosinophils, and T cells. *In vitro* infection of human bronchiolar epithelial cells with RSV induces MCP-1 production (103, 104). In adults with upper respiratory infection due to RSV MCP-1 is increased in nasal secretions during periods of viral shedding (99), although no publications have indicated a similar finding in

infants. MCP-1 is increased in term lambs infected with RSV and further increased in preterm lambs (beyond that of term lambs) infected with RSV (131, 132). Increased expression of MCP-1 may contribute to infiltration of neutrophils and other leukocytes into bronchioles and the lung.

Chemokines, such as RANTES (CCL-5) are chemotactic for T cells, dendritic cells, eosinophils, NK cells, mast cells, and basophils. Contrary to its name, it is not limited to production by T cells; production of RANTES has been reported in platelets, macrophages, eosinophils, fibroblasts, endothelial, epithelial, and endometrial cells (78). Multiple studies on RSV severity and human polymorphisms in RANTES have yielded conflicting results (1, 50, 145), although an interaction or compound effect of polymorphisms at multiple sites yielding specific haplotypes may explain those studies in which no significance was demonstrated (50, 55, 58, 93, 137). A higher ratio of IL-1 to RANTES in nasopharyngeal secretions of infants with RSV was associated with a more severe clinical score (53), and in another study there was an inverse relationship between level of RANTES in tracheal secretions and markers of clinical disease (120). *In vitro* recombinant RANTES inhibited RSV infection of HEp-2 cells (30). Low levels of RANTES in RSV infection could be due to a predisposed deficit or defect in RANTES production (as may be indicated by the haplotype studies), a direct blocking of RANTES by RSV, or indicate consumption during infection. RANTES is not significantly increased in term or preterm lambs infected with RSV; and PD-L1, a negative regulator of T cell function through anergy and reduction of cytotoxicity, is increased in term lambs infected with RSV and further increased in preterm lambs infected with RSV (beyond that of term lambs) (131, 132). Increased levels of CCL2, CCL3, CCL5 CXCL10 are seen in infants with severe RSV bronchiolitis (46, 87).

The cytokines and chemokines reviewed here are not exhaustive in regards to the full innate immune response of the lung to RSV, but emphasize repeatable findings across multiple studies. Additional inflammatory mediators have potentially significant roles in innate defense to RSV infection; however, the current literature on their relationships to RSV is sparse. Interleukin 17 (IL-17) stimulates neutrophil recruitment and stimulates fibroblasts and epithelial cells to secrete cytokines (95). IL-17 was not detected among a population of healthy infants 1-6 months old while it was detected in 15% of RSV-infected infants in the same age range (71). IL-17 levels in nasopharyngeal secretions of infants hospitalized for RSV was increased at discharge compared to time of admission suggesting that IL-17 may be involved with RSV convalescence (33). In contrast, studies in mice suggest that IL-17 can effect regulatory T cells and contribute to increased lesions and inflammation (24, 46). Interferon γ -inducible protein 10 (IP10/CXCL10) is considered a marker of Th1 response and is increased during RSV infection, although its receptor, CXCR3, is decreased when compared to control subjects (114). Interleukins 19 and 20, which are related to IL-10 and induce TNF- α and IL-6 (95), are related to a post-bronchiolitis wheeze similar to IL-10 (32). A polymorphism in interleukin 9 (IL-9) has an opposite effect in boys versus girls, associated with increased susceptibility in boys and protection in girls to severe RSV infection (125).

Interleukin 21 is produced by activated CD4 T cells, natural killer T cells, T follicular helper cells and Th17 cells. IL-21 induces production of inflammatory mediators from epithelial cells and fibroblasts and also mediates differentiation and activity of T, B, and NK cells and thereby restrict differentiation of regulatory T cells. IL-21 has little effect on primary RSV infection in mice but in mice with RSV vaccine-enhanced disease, IL-21 reduced RSV disease severity and lung lesions and expression of IFN γ and IL-17 were associated with enhanced pathology (24).

Effector cells of pulmonary innate immunity and effects of age

The lung parenchyma has structural changes that occur during development and with age that influence innate immune responses and susceptibility to RSV and other pathogens. Premature infants and preterm lambs have increased RSV disease severity compared to healthy adults and the reason for this is not fully elucidated but likely multifactorial (23, 59, 66, 70, 90). The newborn has fewer alveoli that have increased wall thickness compared to adult alveoli. This reduces the efficiency of gaseous exchange and may contribute to more severe clinical symptoms. Submucosal glands are present in a primitive, unbranching structure in human respiratory airways at 13 weeks' gestation and thereafter are present in more distal airways (57). Submucosal gland expression and airway branching patterns of lambs are similar to those of infants (23, 122). The number and differentiation of Clara cells increase in the lung during fetal and perinatal development (9, 10). Clara cell CC10 protein is expressed as early as 10 weeks of gestation in humans (63), and consistently by 15 weeks gestation (9). Type II cells increase in number and further differentiate with fetal age in human and lambs (89, 108).

The vascular endothelium serves a pivotal role in the innate-adaptive immunity interface, responding to innate signals to recruit and adhere to neutrophils, monocytes, dendritic cells, NK, NK T cells, eosinophils, basophils, and lymphocytes and also regulate the permeability of the vascular system to allow leakage of serum. Serum within airways, alveoli and the pulmonary interstitium can dilute microbial agents and provide additional antimicrobial factors such as complement, antibodies, and collectins. There is significant correlation between clinical severity score and total nasal wash leukocyte counts in full term but not preterm infants (4).

Neutrophil infiltration into lung can occur rapidly in response to certain stimuli and release of inflammatory mediators and chemokines such as IL-8. Neutrophil infiltration is a key feature of RSV-induced bronchiolitis. Neutrophils of neonates have reduced proliferation pool, storage pool, and neutrophils in circulation have an impaired response to chemotaxins including reduced rolling adhesion, transmigration, and lamellipodia formation. Neutrophils of infants have reduced function at the site of infection compared to adults (79). Neutrophils express nearly half the level of lactoferrin, 70% of bactericidal/permeability increasing protein (BPI), and have impaired oxidase activity (2, 80, 110). Preterm lambs have reduced levels of myeloperoxidase (131).

Classical monocytes (CD14⁺, CD16⁻) can enter the lung to differentiate into alveolar macrophages whereas non-classical monocytes (CD14^{low}CD16⁻) patrol along the vascular lumen for antigen uptake and presentation and subsequent recruitment of neutrophils and classical monocytes. Following exposure to RSV, monocytes from neonates have a more limited response than adults suggesting a reduced level of adaptive immune responses ability in the neonate (66). *In vitro* stimulation of neonatal monocytes and antigen presenting cells have decreased expression of TNF- α , IFN- α , IFN- γ , IL-12, and IL-1 β , but increased expression of IL-6, IL-8, and IL-10 (79). Monocytes entering lung can differentiate into pulmonary alveolar macrophages (PAMs) that are thereby well-positioned to interact with inhaled substances. While adult mice infected with RSV have a robust response by classically activated alveolar macrophages, responses are reduced in neonatal mice (31). Stimulation of neonatal mouse alveolar macrophages reduces RSV titers and enhanced weight gain (31). Alveolar macrophages of preterm lambs have reduced levels of nitric oxide compared to term lambs (131). Certain species including cattle, horse, pig, sheep, goat, cats, and whales have significant numbers of pulmonary intravascular macrophages (PIMs) (**Fig. 3**). PIMs are not readily detected in human lung; however, they may be

detected in lungs of humans with certain disease conditions such as hepato-pulmonary syndrome (124).

The two major classes of dendritic cells (DCs) are myeloid DCs (mDCs) which express CD11c⁺ and plasmacytoid DCs (pDCs) which are CD11c⁻. As indicated, pDCs produce Type I IFN, especially IFN α with lesser amounts of IFN β . mDCs include mDC1 (CD1c⁺CD141⁻) and mDC2 (CD1c⁻CD141⁺). All three, mDC1, mDC2 and pDCs are infected by RSV and undergo maturation and cell specific cytokine production; however, pDCs are infected at a lower level than mDC1 and mDC2 (60). Dendritic cells (DCs) in neonates are reduced in number and distribution compared to adults and the ratio of myeloid to plasmacytoid DCs is inversed as compared to adults. Neonatal DCs have a reduced ability to produce IFN and decreased ability to stimulate a Th1 response (143). Dendritic cell responses of neonates to RSV have reduced activity compared to adults. RSV-infected DCs co-cultured with T cells of either adults or umbilical cord blood elicited markedly different cytokine profiles with the primary differences attributed to differences in response to TGF- β (138). In mice, neonatal lungs have a deficit in conventional and plasmacytoid dendritic cells along with a shift of cytokines and transcription factors toward Th2 responses (115). Furthermore, infecting neonatal mice with RSV results in enhanced TNF- α initially followed by increased IL-13, mucus hyperproduction, and airway hyperreactivity (144). Pulmonary dendritic cells isolated from term lamb lung differ from those isolated from adult lung in terms of antigen expression and maturation (34-36). Ovine pulmonary dendritic cells from term lung support bRSV replication and have enhanced interleukin (IL)-4 and IL-10 gene transcripts (34-36)

RSV and other viral infections stimulate infiltration of CD4⁺ and CD8⁺ which, along with DC's and other cell types, influence Th1 and Th2 cytokines. Formalin-inactivate RSV

vaccines also enhance RSV disease in humans and many models. IL-21 production in vaccine-enhanced RSV disease, for example, can affect regulatory T cells, reduce IL-17 and in this way control inflammatory responses within bronchioles, the site of RSV infection and lesion development (24). These are adaptive responses reviewed elsewhere and beyond the scope of this review of pulmonary innate immunity (21, 46). However, there is considerable overlap between the innate and adaptive immune systems in contributing and regulating T helper cells responses as a number of the innate factors are integral to priming and directing the adaptive response. Advances in understanding innate immunity will likely contribute to more precise and effective adaptive responses as well as create a more complete picture of RSV disease and immunity.

Discussion/conclusion

From the above review, it is clear that the innate immune response is important in RSV infection, and a better understanding of it, as well as how to modulate it, could make a significant contribution to RSV prevention and therapy in infants. Enhancement of innate immune responses may reduce RSV disease severity or prevent initial infection. Also, because many innate immune responses stimulate adaptive immune responses, enhanced activation of innate immune responses may bolster/strengthen adaptive responses. Innate immune responses require some level of lung maturation and activity of single cell types in some cases (e.g., surfactant protein A production by type II cells) or several cell types (epithelial and submucosal glands for Duox/LPO oxidative defense) (37, 38). Enhancement of pulmonary maturation may bolster innate responses and studies in lambs have demonstrated that vascular endothelial growth factor (VEGF) administration intratracheally prior to RSV infection reduces disease severity (92, 102). VEGF expression by development lung is vital for maturation and differentiation and exogenously administer

VEGF up-regulates SP-A, induces monocyte infiltration, and can contribute to vascular leak (102). Thus, therapies such as VEGF may activate aspects of the innate immune response and simultaneously trigger other defense mechanisms with potential enhancement of adaptive responses. There are also novel genetic vaccines, microparticles, therapies targeting the RSV receptor, L-polymerase inhibitors, therapies that promote enhancement of TLR4 signaling intensity, therapies that target of the recently discovered RSV receptor, nucleolin and many others giving hope for effective prophylactic and therapeutic strategies.

Despite what is known about pulmonary innate immune responses to virus such as RSV by the neonatal lung there is much to be learned. Many cellular mechanisms of innate immune products have yet to be fully defined in the newborn respiratory tract, including: inhibitory RNA (iRNA) regulation of innate immune gene expression, expression and down-regulation of innate immune gene receptors by the various cell types, the extent to which immature or poorly differentiated cells can produce innate immune products, and the extent to which sequestration of inflammatory and innate immune mediators by extracellular matrix proteoglycans differs in newborn versus adult respiratory tract.

Acknowledgements

This work was funded in part by NIH/NIAID 1R56AI091000-01A1, and NIH/NIAID R01AI062787, Gilead Sciences, Inc., and Meridian Bioscience, Inc, MedImmune, LLC. The authors thank Dr. Albert Van Geelen, Jack Gallup, and the many others who have contributed to the studies.

REFERENCES

1. Amanatidou V, Sourvinos G, Apostolakis S, Neonaki P, Tsilimigaki A, Krambovitis E, Spandidos DA. Rantes promoter gene polymorphisms and susceptibility to severe respiratory syncytial virus-induced bronchiolitis. *Pediatr Infect Dis J* 27:38-42, 2008.
2. Ambruso DR, Bentwood B, Henson PM, Johnston RB, Jr. Oxidative metabolism of cord blood neutrophils: Relationship to content and degranulation of cytoplasmic granules. *Pediatr Res* 18:1148-1153, 1984.
3. Ampuero S, Luchsinger V, Tapia L, Palomino MA, Larranaga CE. Sp-a1, sp-a2 and sp-d gene polymorphisms in severe acute respiratory syncytial infection in chilean infants. *Infect Genet Evol* 11:1368-1377, 2011
4. Assefa D, Amin N, Dozor AJ, Parton LA. Attenuated interleukin-8/leukocyte immunoresponse in preterm infants compared with term infants hospitalized with respiratory syncytial virus bronchiolitis: A pilot study. *Hum Immunol*;72:708-711, 2011
5. Ashcroft GS. Bidirectional regulation of macrophage function by tgf-beta. *Microbes Infect* 1:1275-1282, 1999
6. Atreya PL, Kulkarni S. Respiratory syncytial virus strain a2 is resistant to the antiviral effects of type i interferons and human mxa. *Virology* 261:227-241, 1999
7. Awomoyi AA, Rallabhandi P, Pollin TI, Lorenz E, Szein MB, Boukhvalova MS, Hemming VG, Blanco JC, Vogel SN. Association of tlr4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. *J Immunol* 179:3171-3177, 2007
8. Barlow PG, Beaumont PE, Cosseau C, Mackellar A, Wilkinson TS, Hancock RE, Haslett C, Govan JR, Simpson AJ, Davidson DJ. The human cathelicidin LL-37 preferentially promotes apoptosis of infected airway epithelium. *Am J Respir Cell Mol Biol*;43:692-702, 2010
9. Barth PJ, Wolf M, Ramaswamy A. Distribution and number of clara cells in the normal and disturbed development of the human fetal lung. *Pediatr Pathol* 14:637-651, 1994
10. Barth PJ, Koch S, Muller B, Unterstab F, von Wichert P, Moll R. Proliferation and number of clara cell 10-kda protein (cc10)-reactive epithelial cells and basal cells in normal, hyperplastic and metaplastic bronchial mucosa. *Virchows Arch* 437:648-655, 2000.
11. Boers JE, Ambergen AW, Thunnissen FB. Number and proliferation of clara cells in normal human airway epithelium. *Am J Respir Crit Care Med* 159:1585-1591, 1999
12. Bonville CA, Rosenberg HF, Domachowske JB. Macrophage inflammatory protein-1alpha and rantes are present in nasal secretions during ongoing upper respiratory tract infection. *Pediatr Allergy Immunol* 10:39-44, 1999
13. Bowdish DM, Davidson DJ, Hancock RE. Immunomodulatory properties of defensins and cathelicidins. *Curr Top Microbiol Immunol* 306:27-66, 2006
14. Braido F, Riccio AM, Guerra L, Gamalero C, Zolezzi A, Tarantini F, De Giovanni B, Folli C, Descalzi D, Canonica GW. Clara cell 16 protein in copd sputum: A marker of small airways damage? *Respir Med* 101:2119-2124, 2007
15. Brogden KA, Kalfa VC, Ackermann MR, Plamquist DE, McCray PB, Jr., Tack BF: The ovine cathelicidin SMAP29 kills ovine respiratory pathogens in vitro and in an in vivo model of pulmonary infection. *Antimicrobial Agents and Chemo* 45: 331-334, 2001
16. Bruce SR, Atkins CL, Colasurdo GN, Alcorn JL. Respiratory syncytial virus infection alters surfactant protein a expression in human pulmonary epithelial cells by reducing translation efficiency. *Am J Physiol Lung Cell Mol Physiol* 297:L559-567, 2009
17. Burri, P.H. Fetal and postnatal development of the lung. *Annu Rev Physiol* 46, 617-628, 1984

18. Button B, Cai LH, Ehre C, Kesimer M, Hill DB, Sheehan JK, Boucher RC, Rubinstein M. A periciliary brush promotes lung health by separating the mucus layer from airway epithelia. *Science* 337:937-941, 2012
19. Castell JV, Donato MT, Gomez-Lechon MJ. Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach. *Exp Toxicol Pathol* 57 Suppl 1:189-204, 2007
20. Chieux V, Hober D, Chehadeh W, Harvey J, Alm G, Cousin J, Ducoulombier H, Wattre P. Mxa protein in capillary blood of children with viral infections. *J Med Virol* 59:547-551, 1999
21. Collins, P.L.; Melero, J.A. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. *Virus Res* 162, 80-99, 2011
22. Conner GE, Salathe M, Forteza R. Lactoperoxidase and hydrogen peroxide metabolism in the airway. *Am J Respir Crit Care Med* 166:S57-61, 2002
23. Derscheid RJ, Ackermann MR: Perinatal lamb model of respiratory syncytial virus (RSV) infection. *Viruses* (accepted for publication), 2013
24. Dodd JS, Clark D, Muir R, Korpis C, Openshaw PJ. Endogenous IL-21 regulates pathogenic mucosal CD4 T-cell responses during enhanced RSV disease in mice. *Mucosal Immunol* (Epub), 2012
25. Domachowske JB, Bonville CA, Gao JL, Murphy PM, Easton AJ, Rosenberg HF. Mip-1alpha is produced but it does not control pulmonary inflammation in response to respiratory syncytial virus infection in mice. *Cell Immunol* 206:1-6, 2000
26. Douville RN, Lissitsyn Y, Hirschfeld AF, Becker AB, Kozyrskyj AL, Liem J, Bastien N, Li Y, Victor RE, Sekhon M, et al. Tlr4 asp299gly and thr399ile polymorphisms: No impact on human immune responsiveness to lps or respiratory syncytial virus. *PLoS One*;5:e12087, 2010
27. Dubin RF, Robinson SK, Widdicombe JH. Secretion of lactoferrin and lysozyme by cultures of human airway epithelium. *Am J Physiol Lung Cell Mol Physiol* 286:L750-755, 2004
28. El Saleeby CM, Li R, Somes GW, Dahmer MK, Quasney MW, DeVincenzo JP. Surfactant protein a2 polymorphisms and disease severity in a respiratory syncytial virus-infected population. *J Pediatr* 156:409-414, 2009
29. Elizur A, Adair-Kirk TL, Kelley DG, Griffin GL, deMello DE, Senior RM. Clara cells impact the pulmonary innate immune response to lps. *Am J Physiol Lung Cell Mol Physiol* 293:L383-392, 2007
30. Elliott MB, Tebbey PW, Pryharski KS, Scheuer CA, Laughlin TS, Hancock GE. Inhibition of respiratory syncytial virus infection with the cc chemokine rantes (ccl5). *J Med Virol* 73:300-308, 2004
31. Empey KM, Orend JG, Peebles RS Jr, Egaña L, Norris KA, Oury TD, Kolls JK: Stimulation of immature lung macrophages with intranasal interferon gamma in a novel neonatal mouse model of respiratory syncytial virus infection. *PLoS One*. 7(7):e40499, (ePub), 2012
32. Ermers MJ, Janssen R, Onland-Moret NC, Hodemaekers HM, Rovers MM, Houben ML, Kimpen JL, Bont LJ. Il10 family member genes il19 and il20 are associated with recurrent wheeze after respiratory syncytial virus bronchiolitis. *Pediatr Res* 70:518-523, 2010.
33. Faber TE, Groen H, Welfing M, Jansen KJ, Bont LJ. Specific increase in local IL-17 production during recovery from primary RSV bronchiolitis. *J Med Virol*. 84(7):1084-1088, 2012
34. Fach, S.J.; Brockmeier, S.L.; Hobbs, L.A.; Lehmkuhl, H.D.; Sacco, S.E. Pulmonary dendritic cells isolated from neonatal and adult ovine lung tissue. *Vet Immunol Immun Pathol* 112, 171-182, 2007
35. Fach, S.J.; Meyerholz, D.K.; Gallup, J.M.; Ackermann, M.R.; Lehmkuhl, H.D.; Sacco, R.E. Neonatal ovine pulmonary dendritic cells support bovine respiratory syncytial virus

replication with enhanced interleukin (IL)-4 and IL-10 gene transcripts. *Viral Immunol* 20, 119-130, 2007

36. Fach, S.J.; Olivier, A.; Gallup, J.M.; Waters, T.E.; Ackermann, M.R.; Lehmkuhl, H.D.; Sacco, R.E. Differential expression of cytokine transcripts in neonatal and adult ovine alveolar macrophages in response to respiratory syncytial virus or toll-like receptor ligation. *Vet Immunol Immunopathol* 136, 55-64, 2010
37. Fischer AJ, Lennemann NJ, Krishnamurthy S, Pocza P, Durairaj L, Launspach JL, Rhein BA, Wohlford-Lenane C, Lorentzen D, Banfi B, et al. Enhancement of respiratory mucosal antiviral defenses by the oxidation of iodide. *Am J Respir Cell Mol Biol* 45:874-881, 2011.
38. Fragoso MA, Fernandez V, Forteza R, Randell SH, Salathe M, Conner GE. Transcellular thiocyanate transport by human airway epithelia. *J Physiol* 561:183-194, 2004.
39. Gagro A, Tominac M, Krsulovic-Hresic V, Bace A, Matic M, Drazenovic V, Mlinaric-Galinovic G, Kosor E, Gotovac K, Bolanca I, et al. Increased toll-like receptor 4 expression in infants with respiratory syncytial virus bronchiolitis. *Clin Exp Immunol* 135:267-272, 2004
40. Garofalo RP, Patti J, Hintz KA, Hill V, Ogra PL, Welliver RC. Macrophage inflammatory protein-1alpha (not t helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. *J Infect Dis* 184:393-399, 2001
41. Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R. Interferon-gamma: Biologic functions and hcv therapy (type i/ii) (2 of 2 parts). *Clin Ter* 157:457-468, 2006
42. Gill S, Wight TN, Frevert CW. Proteoglycans: key regulators of pulmonary inflammation and the innate immune response to lung infect. *Anat Rec* 293:968-981, 2010
43. Griesse M. Respiratory syncytial virus and pulmonary surfactant. *Viral Immunol* 15:357-363, 2002
44. Grubor B, Gallup JM, Meyerholz DK, Crouch EC, Evans RB, Brogden KA, Lehmkuhl HD, Ackermann MR. Enhanced surfactant protein and defensin mRNA levels and reduced viral replication during parainfluenza virus type 3 pneumonia in neonatal lambs. *Clin Diagn Lab Immunol* 11:599-607, 2004
45. Guerrero-Plata A, Casola A, Suarez G, Yu X, Spetch L, Peeples ME, Garofalo RP. Differential response of dendritic cells to human metapneumovirus and respiratory syncytial virus. *Am J Respir Cell Mol Biol* 34:320-329, 2006
46. Habibi MS, Openshaw PJM: Benefit and harm from immunity to respiratory syncytial virus: implications for treatment. *Curr Opin Infect Dis* 25:687-694, 2012
47. Haeblerle HA, Kuziel WA, Dieterich HJ, Casola A, Gatalica Z, Garofalo RP. Inducible expression of inflammatory chemokines in respiratory syncytial virus-infected mice: Role of mip-1alpha in lung pathology. *J Virol* 75:878-890, 2001
48. Haller O, Kochs G. Human mxa protein: An interferon-induced dynamin-like gtpase with broad antiviral activity. *J Interferon Cytokine Res* 31:79-87, 2011
49. Harty RN, Pitha PM, Okumura A. Antiviral activity of innate immune protein isg15. *J Innate Immun* 1:397-404, 2009
50. Hattori S, Shimojo N, Mashimo T, Inoue Y, Ono Y, Kohno Y, Okamoto Y, Hata A, Suzuki Y. Relationship between rantes polymorphisms and respiratory syncytial virus bronchiolitis in a Japanese infant population. *Jpn J Infect Dis* 64:242-245, 2011
51. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. *J Virol* 75:10730-10737, 2001
52. Hiemstra PS. The role of epithelial beta-defensins and cathelicidins in host defense of the lung. *Exp Lung Res* 33:537-542, 2007

53. Hornsleth A, Loland L, Larsen LB. Cytokines and chemokines in respiratory secretion and severity of disease in infants with respiratory syncytial virus (rsv) infection. *J Clin Virol* 21:163-170, 2001
54. Horwitz DA, Gray JD, Ohtsuka K. Role of nk cells and tgf-beta in the regulation of t-cell-dependent antibody production in health and autoimmune disease. *Microbes Infect* 1:1305-1311, 1999
55. Jafri HS, Chavez-Bueno S, Mejias A, Gomez AM, Rios AM, Nassi SS, Yusuf M, Kapur P, Hardy RD, Hatfield J, et al. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. *J Infect Dis* 189:1856-1865, 2004.
56. Janssen R, Bont L, Siezen CL, Hodemaekers HM, Ermers MJ, Doornbos G, van 't Slot R, Wijmenga C, Goeman JJ, Kimpen JL, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. *J Infect Dis* 196:826-834, 2007
57. Jeffery PK, Gaillard D, Moret S. Human airway secretory cells during development and in mature airway epithelium. *Eur Respir J* 5:93-104, 1992
58. John AE, Berlin AA, Lukacs NW. Respiratory syncytial virus-induced ccl5/rantes contributes to exacerbation of allergic airway inflammation. *Eur J Immunol* 33:1677-1685, 2003
59. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. *Mod Pathol* 20:108-119, 2007
60. Johnson TR, Johnson CN, Corbett KS, Edwards GC, Graham BS: Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus. *PLoS ONE* 6(1): e16458 (1-13), 2011
61. Kawashima K, Meyerholz DK, Gallup JM, Grubor B, Lazic T, Lehmkuhl HD, Ackermann MR. Differential expression of ovine innate immune genes by preterm and neonatal lung epithelia infected with respiratory syncytial virus. *Viral Immunol* 19:316-323, 2006
62. Kerr MH, Paton JY. Surfactant protein levels in severe respiratory syncytial virus infection. *Am J Respir Crit Care Med* 159:1115-1118, 1999
63. Khor A, Gray ME, Singh G, Stahlman MT. Ontogeny of clara cell-specific protein and its mrna: Their association with neuroepithelial bodies in human fetal lung and in bronchopulmonary dysplasia. *J Histochem Cytochem* 44:1429-1438, 1996
64. Kim KC: Role of epithelial mucins during airway infection. *Pulm Pharm and Therapeut* 25:415-419, 2012
65. Kota S, Sabbah A, Chang TH, Harnack R, Xiang Y, Meng X, Bose S. Role of human beta-defensin-2 during tumor necrosis factor-alpha/nf-kappab-mediated innate antiviral response against human respiratory syncytial virus. *J Biol Chem* 283:22417-22429, 2008
66. Krishnan S, Craven M, Welliver RC, Ahmad N, Halonen M. Differences in participation of innate and adaptive immunity to respiratory syncytial virus in adults and neonates. *J Infect Dis* 188: 433–439, 2008
67. Kristiansen H, Gad HH, Eskildsen-Larsen S, Despres P, Hartmann R. The oligoadenylate synthetase family: An ancient protein family with multiple antiviral activities. *J Interferon Cytokine Res* 31:41-47, 2011
68. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, et al. Pattern recognition receptors tlr4 and cd14 mediate response to respiratory syncytial virus. *Nat Immunol* 1:398-401, 2000
69. Lahti M, Lofgren J, Marttila R, Renko M, Klaavuniemi T, Haataja R, Ramet M, Hallman M. Surfactant protein d gene polymorphism associated with severe respiratory syncytial virus infection. *Pediatr Res* 51:696-699, 2002

70. Lapin CD, Hiatt PW, Langston C, Mason E, Piedra PT. A lamb model for human respiratory syncytial virus infection. *Pediatr Pulmonol* 15:151-156, 1993
71. Larranaga CL, Ampuero SL, Luchsinger VF, Carrion FA, Aguilar NV, Morales PR, Palomino MA, Tapia LF, Avendano LF. Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus. *Pediatr Infect Dis J* 28:867-873, 2009
72. Lazic, T.; Sow, F.B.; Van Geelen, A.; Meyerholz, D.K.; Gallup, J.M.; Ackermann, M.R. Exposure to ethanol during the last trimester of pregnancy alters the maturation and immunity of the fetal lung. *Alcohol* 45, 673-680, 2011
73. Legrand D, Ellass E, Carpentier M, Mazurier J. Interactions of lactoferrin with cells involved in immune function. *Biochem Cell Biol* 84:282-290, 2006
74. Legrand D, Ellass E, Pierce A, Mazurier J. Lactoferrin and host defence: An overview of its immuno-modulating and anti-inflammatory properties. *Biometals* 17:225-229, 2004
75. Legrand D, Mazurier J. A critical review of the roles of host lactoferrin in immunity. *Biometals* 23:365-376, 2010
76. LeVine AM, Elliott J, Whitsett JA, Srikiatkachorn A, Crouch E, DeSilva N, Korfhagen T. Surfactant protein-d enhances phagocytosis and pulmonary clearance of respiratory syncytial virus. *Am J Respir Cell Mol Biol* 31:193-199, 2004
77. LeVine AM, Gwozdz J, Stark J, Bruno M, Whitsett J, Korfhagen T. Surfactant protein-a enhances respiratory syncytial virus clearance in vivo. *J Clin Invest* 103:1015-1021, 1999
78. Levy JA. The unexpected pleiotropic activities of rantes. *J Immunol* 182:3945-3946, 2009
79. Levy O. Innate immunity of the newborn: Basic mechanisms and clinical correlates. *Nat Rev Immunol* 7:379-390, 2007
80. Levy O, Martin S, Eichenwald E, Ganz T, Valore E, Carroll SF, Lee K, Goldmann D, Thorne GM. Impaired innate immunity in the newborn: Newborn neutrophils are deficient in bactericidal/permeability-increasing protein. *Pediatrics* 104:1327-1333, 1999
81. Li HN, Barlow PG, Bylund J, Mackellar A, Bjorstad A, Conlon J, Hiemstra PS, Haslett C, Gray M, Simpson AJ, et al. Secondary necrosis of apoptotic neutrophils induced by the human cathelicidin LL-37 is not proinflammatory to phagocytosing macrophages. *J Leukoc Biol* 86:891-902, 2009
82. Lindgren C, Groggaard J. Reflex apnoea response and inflammatory mediators in infants with respiratory tract infection. *Acta Paediatr* 85:798-803, 1996
83. Liu P, Jamaluddin M, Li K, Garofalo RP, Casola A, Brasier AR. Retinoic acid-inducible gene i mediates early antiviral response and toll-like receptor 3 expression in respiratory syncytial virus-infected airway epithelial cells. *J Virol* 81:1401-1411, 2007
84. Lofgren J, Marttila R, Renko M, Ramet M, Hallman M. Toll-like receptor 4 asp299gly polymorphism in respiratory syncytial virus epidemics. *Pediatr Pulmonol* 45:687-692, 2010
85. Lukacs, N.W.; Smitt, J.J.; Mukherjee, S.; Morris, S.B.; Nunez, G.; Lindell, D.M. Respiratory virus-induced TLR7 activation controls IL-17-associated increased mucus via IL-23 regulation. *J Immunol* 185, 2231-2239, 2010
86. Maurer M, von Stebut E. Macrophage inflammatory protein-1. *Int J Biochem Cell Biol* 36:1882-1886, 2004
87. McNamara PS, Flanagan BF, Hart CA, Smyth RL: Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. *J Infect Dis* 191:1225-1232, 2005
88. McNamara, Flanagan BF, Selby AM et al: Pro- and anti-inflammatory responses in respiratory syncytial virus bronchiolitis. *Eur Respir J* 23:106-112, 2004
89. Meyerholz, D.K.; DeGraaff, J.A.; Gallup, J.M.; Ackermann, M.R. Depletion of alveolar glycogen corresponds with immunohistochemical development of CD208 antigen expression in perinatal lamb lung. *J Histochem Cytochem* 54, 1247-1253, 2006

90. Meyerholz, D.K.; Grubor, B.; Fach, S.J.; Sacco, R.E.; Lehmkuhl, H.D.; Gallup, J.M.; Ackermann, M.R. Reduced clearance of respiratory syncytial virus in a preterm lamb model. *Microbes and Infection* 6, 1312-1319., 2004
91. Meyerholz DK, Kawashima K, Gallup JM, Grubor B, Ackermann MR. Expression of select immune genes (surfactant proteins a and d, sheep beta defensin 1, and toll-like receptor 4) by respiratory epithelia is developmentally regulated in the preterm neonatal lamb. *Dev Comp Immunol* 30:1060-1069, 2006
92. Meyerholz, D.K.; Gallup, J.M.; Lazic, T.; de Macedo, M.M.A.; Lehmkuhl, H.D.; Ackermann, M.R. Pretreatment with recombinant human vascular endothelial growth factor reduces virus replication and inflammation in a perinatal lamb model of RSV infection. *Viral Immunology* 20, 188-196, 2007
93. Miller AL, Bowlin TL, Lukacs NW. Respiratory syncytial virus-induced chemokine production: Linking viral replication to chemokine production in vitro and in vivo. *J Infect Dis* 189:1419-1430, 2004
94. Murai H, Terada A, Mizuno M, Asai M, Hirabayashi Y, Shimizu S, Morishita T, Kakita H, Hussein MH, Ito T, et al. Il-10 and rantes are elevated in nasopharyngeal secretions of children with respiratory syncytial virus infection. *Allergol Int* 56:157-163, 2007
95. Murphy K, Travers, P., Walport, M., editor. *Janeway's immunobiology*. New York: Garland Science, Taylor & Francis Group, LLC; 2008.
96. Murawski MR, Bowen GN, Cerny AM, Anderson LJ, Haynes LM, Tripp RA, Kurt-Jones EA, Finberg RW. Respiratory syncytial virus activates innate immunity through toll-like receptor 2. *J Virol* 83:1492-1500, 2009
97. Nair, H.; Nokes, D.J.; Gessner, B.D.; Dherani, M.; Madhi, S.A.; Singleton, R.J.; O'Brien, K.L.; Roca, A.; Wright, P.F.; Bruce, N. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. *Lancet* 375, 1545-1555, 2010
98. Neilson KA, Yunis EJ. Demonstration of respiratory syncytial virus in an autopsy series. *Pediatr Pathol* 10:491-502, 1990
99. Noah TL, Becker S. Chemokines in nasal secretions of normal adults experimentally infected with respiratory syncytial virus. *Clin Immunol* 97:43-49, 2000
100. Ohtsuki Y, Nakanishi N, Fujita J, Yoshinouchi T, Kobayashi M, Ueda N, Lee GH, Furihata M. Immunohistochemical distribution of sp-d, compared with that of sp-a and kl-6, in interstitial pneumonias. *Med Mol Morphol* 40:163-167, 2007
101. Olivier, A.; Gallup, J.M.; de Macedo, M.M.; Varga, S.M.; Ackermann, M.R. Human respiratory syncytial virus A2 strain replicates and induces innate immune responses by respiratory epithelia of neonatal lambs. *Int J Exp Pathol* 90, 431-438, 2009
102. Olivier AK, Gallup JM, van Geelen A, Ackermann MR. Exogenous administration of vascular endothelial growth factor prior to human respiratory syncytial virus a2 infection reduces pulmonary pathology in neonatal lambs and alters epithelial innate immune responses. *Exp Lung Res* 37:131-143, 2011
103. Olszewska-Pazdrak B, Casola A, Saito T, Alam R, Crowe SE, Mei F, Ogra PL, Garofalo RP. Cell-specific expression of rantes, mcp-1, and mip-1alpha by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. *J Virol* 72:4756-4764, 1998
104. Oshansky CM, Barber JP, Crabtree J, Tripp RA. Respiratory syncytial virus f and g proteins induce interleukin 1alpha, cc, and cxc chemokine responses by normal human bronchoepithelial cells. *J Infect Dis* 201:1201-1207. 2010
105. Paulus SC, Hirschfeld AF, Victor RE, Brunstein J, Thomas E, Turvey SE. Common human toll-like receptor 4 polymorphisms--role in susceptibility to respiratory syncytial virus infection and functional immunological relevance. *Clin Immunol* 123:252-257, 2007

106. Perni SC, Vardhana S, Kalish R, Chasen S, Witkin SS. Clara cell protein 16 concentration in mid-trimester amniotic fluid: Association with fetal gender, fetal g>a +38 cc16 gene polymorphism and pregnancy outcome. *J Reprod Immunol* 68:85-90, 2005.
107. Pfaller CK, Li Z, George CX, Samuel CE. Protein kinase pkr and rna adenosine deaminase adar1: New roles for old players as modulators of the interferon response. *Curr Opin Immunol* 23:573-582, 2011
108. Plopper CG, Mariassy AT, Hill LH. Ultrastructure of the nonciliated bronchiolar epithelial (clara) cell of mammalian lung: I. A comparison of rabbit, guinea pig, rat, hamster, and mouse. *Exp Lung Res* 1:139-154, 1980
109. Puthothu B, Forster J, Heinzmann A, Krueger M. Tlr-4 and cd14 polymorphisms in respiratory syncytial virus associated disease. *Dis Markers* 22:303-308, 2006
110. Qing G, Rajaraman K, Bortolussi R. Diminished priming of neonatal polymorphonuclear leukocytes by lipopolysaccharide is associated with reduced cd14 expression. *Infect Immun* 63:248-252, 1995
111. Rallabhandi P, Phillips RL, Boukhvalova MS, Pletneva LM, Shirey KA, Gioannini TL, Weiss JP, Chow JC, Hawkins LD, Vogel SN, Blanco JC: Respiratory syncytial virus fusion protein-induced toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4 antagonists *Rhodobacter sphaeroides* lipopolysaccharide and eritoran (E5564) and requires direct interaction with MD-2. *MBio* 3:218-212, 2012
112. Ramsay PL, DeMayo FJ, Hegemier SE, Wearden ME, Smith CV, Welty SE. Clara cell secretory protein oxidation and expression in premature infants who develop bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 164:155-161, 2001
113. Ramsay PL, Luo Z, Magdaleno SM, Whitbourne SK, Cao X, Park MS, Welty SE, Yu-Lee LY, DeMayo FJ. Transcriptional regulation of ccsp by interferon-gamma in vitro and in vivo. *Am J Physiol Lung Cell Mol Physiol* 284:L108-118, 2003
114. Roe MF, Bloxham DM, Cowburn AS, O'Donnell DR. Changes in helper lymphocyte chemokine receptor expression and elevation of ip-10 during acute respiratory syncytial virus infection in infants. *Pediatr Allergy Immunol* 22:229-234, 2010
115. Roux X, Remot A, Petit-Camurdan A, Nahori M-A, Kiefer-Biasizzo H, Marchal G, Lagranderie M, Riffault S: Neonatal lung immune responses show a shift of cytokines and transcription factors toward Th2 and a deficit in conventional and plasmacytoid dendritic cells. *Eur J Immunol* 41:2852-2861, 2011
116. Rudd BD, Burstein E, Duckett CS, Li X, Lukacs NW. Differential role for tlr3 in respiratory syncytial virus-induced chemokine expression. *J Virol* 79:3350-3357, 2005
117. Sano H, Nagai K, Tsutsumi H, Kuroki Y. Lactoferrin and surfactant protein a exhibit distinct binding specificity to f protein and differently modulate respiratory syncytial virus infection. *Eur J Immunol* 33:2894-2902, 2003
118. Schutte, McCray, β -defensins in lung host defense. *Annu Rev Physiol* 64:709-748, 2002
119. Segovia J, Sabbah A, Mgbemena V, Tsai SY, Chang TH, Berton MT, Morris IR, Allen IC, Ting JP, Bose S. Tlr2/myd88/nf-kappab pathway, reactive oxygen species, potassium efflux activates nlrp3/asc inflammasome during respiratory syncytial virus infection. *PLoS One* 7:e29695. 2012
120. Sheeran P, Jafri H, Carubelli C, Saavedra J, Johnson C, Krisher K, Sanchez PJ, Ramilo O. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. *Pediatr Infect Dis J* 18:115-122, 1999.
121. Shijubo N, Itoh Y, Yamaguchi T, Abe S. Development of an enzyme-linked immunosorbent assay for clara cell 10-kda protein: In pursuit of clinical significance of sera in patients with asthma and sarcoidosis. *Ann N Y Acad Sci* 923:268-279, 2000.

122. Scheerlinck JP, Snibson KJ, Bowles VM, Sutton P. Biomedical applications of sheep models: From asthma to vaccines. *Trends Biotechnol* 26:259-266, 2008
123. Schlender J, Bossert B, Buchholz U, Conzelmann KK. Bovine respiratory syncytial virus nonstructural proteins ns1 and ns2 cooperatively antagonize alpha/beta interferon-induced antiviral response. *J Virol* 74:8234-8242, 2000
124. Schneberger D, Aharonson-Raz K, Singh B. Pulmonary intravascular macrophages and lung health: what are we missing? *Am J Physiol Lung Cell Mol Physiol*. 302(6):L498-503, 2012
125. Schuurhof A, Bont L, Siezen CL, Hodemaekers H, van Houwelingen HC, Kimman TG, Hoebee B, Kimpen JL, Janssen R. Interleukin-9 polymorphism in infants with respiratory syncytial virus infection: An opposite effect in boys and girls. *Pediatr Pulmonol* 45:608-613, 2010
126. Schuurhof A, Janssen R, de Groot H, Hodemaekers HM, de Klerk A, Kimpen JL, Bont L. Local interleukin-10 production during respiratory syncytial virus bronchiolitis is associated with post-bronchiolitis wheeze. *Respir Res*;12:121, 2011
127. Semple MG, Dankert HM, Ebrahimi B, Correia JB, Booth JA, Stewart JP, Smyth RL, Hart CA. Severe respiratory syncytial virus bronchiolitis in infants is associated with reduced airway interferon gamma and substance p. *PLoS One* ;2:e1038, 2007
128. Singh G, Katyal SL. Clara cell proteins. *Ann N Y Acad Sci* 923:43-58, 2000
129. Smiley-Jewell SM, Nishio SJ, Weir AJ, Plopper CG. Neonatal clara cell toxicity by 4-ipomeanol alters bronchiolar organization in adult rabbits. *Am J Physiol* 1998;274:L485-498.
130. Smiley-Jewell SM, Plopper CG. Proliferation during early phases of bronchiolar repair in neonatal rabbits following lung injury by 4-ipomeanol. *Toxicol Appl Pharmacol* 192:69-77, 2003
131. Sow, F.B.; Gallup, J.M.; Krishnan, S.; Patera, A.C.; Suzich, J.; Ackermann, M.R. Respiratory syncytial virus infection is associated with an altered innate immunity and a heightened pro-inflammatory response in the lungs of preterm lambs. *Resp Res* 12, 106, 2011
132. Sow FB, Gallup JM, Olivier A, Krishnan S, Patera AC, Suzich J, Ackermann MR. Respiratory syncytial virus is associated with an inflammatory response in lungs and architectural remodeling of lung-draining lymph nodes of newborn lambs. *Am J Physiol Lung Cell Mol Physiol* 300:L12-24, 2011
133. Sow FB, Gallup JM, Derscheid R, Krishnan S, Ackermann MR. Ontogeny of the immune response in the ovine lung. *Immunol Invest*. 41:304-316, 2012
134. Stavnezer J. Regulation of antibody production and class switching by tgf-beta. *J Immunol* 155:1647-1651, 1995
135. Swedan S, Andrews J, Majumdar T, Musiyenko A, Barik S. Multiple functional domains and complexes of the two nonstructural proteins of human respiratory syncytial virus contribute to interferon suppression and cellular location. *J Virol* 85:10090-10100, 2011
136. Tayyari F, Marchant D, Moraes TJ, Duan W, Mastrangelo P, Hegele RG: Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. *Nat Med* 17:1132-1136, 2011
137. Tekkanat KK, Maassab H, Miller A, Berlin AA, Kunkel SL, Lukacs NW. Rantes (ccl5) production during primary respiratory syncytial virus infection exacerbates airway disease. *Eur J Immunol* 32:3276-3284, 2002
138. Thornburg NJ, Shepherd B, Crowe JE, Jr. Transforming growth factor beta is a major regulator of human neonatal immune responses following respiratory syncytial virus infection. *J Virol* 84:12895-12902, 2010
139. Varelle M, Kieninger E, Edwards MR, Regamey N. The airway epithelium: soldier in the fight against respiratory viruses. *Clin Microbiol Rev*. 24(1):210-29, 2011

140. Wahl SM, McCartney-Francis N, Allen JB, Dougherty EB, Dougherty SF. Macrophage production of $\text{tgf-}\beta$ and regulation by $\text{tgf-}\beta$. *Ann N Y Acad Sci* 593:188-196, 1990
141. Wang SZ, Rosenberger CL, Bao YX, Stark JM, Harrod KS. Clara cell secretory protein modulates lung inflammatory and immune responses to respiratory syncytial virus infection. *J Immunol* 171:1051-1060, 2003
142. Wijkstrom-Frei C, El-Chemaly S, Ali-Rachedi R, Gerson C, Cobas MA, Forteza R, Salathe M, Conner GE. Lactoperoxidase and human airway host defense. *Am J Respir Cell Mol Biol* 29:206-212, 2003
143. Willems F, Vollstedt S, Suter M. Phenotype and function of neonatal dc. *Eur J Immunol* 39:26-35, 2009
144. You D, Becnel D, Wang K, Ripple M, Daly M. Cormier SA: Exposure of neonates to respiratory syncytial virus is critical in determining subsequent airway response in adults. *Respir Res* 7, 107-117, 2006
145. Zhao DY, Wen GY, Tian M, Shi SY, Chen RH. [association of rantes gene promoter -28c/g polymorphism with respiratory syncytial virus bronchiolitis]. *Zhonghua Er Ke Za Zhi* 46:89-93, 2008.

Table 1. Antimicrobial products from epithelia of the respiratory airways and alveoli that contribute to innate defense (Adapted from 118; Schutte, McCray, β -defensins in lung host defense. *Annu Rev Physiol* 64:709-748, 2002).

Product	Source	Activity
Lysozyme	epithelia, neutrophils, macrophages	Microbicidal
Lactoferrin	epithelia, neutrophils	Iron sequestration
Secretory leukocyte protease inhibitor (SLPI)	epithelia, macrophages	Microbicidal, anti-protease
IgA secretory component	epithelia	Opsonization
Phospholipase A2 (PLA ₂)	epithelial, neutrophils	Microbicidal
Surfactant protein A (SP-A)	epithelia	Opsonizes and aggregates RSV, activates macrophages
Surfactant protein D (SP-D)	epithelia	Opsonizes and aggregates RSV, activates macrophages
Defensins (α , β , θ)	epithelia, neutrophils, macrophages	Microbicidal, leukocyte activation, dendritic cell chemotaxis
Cathelicidins	neutrophils, epithelia	Microbicidal
Anionic peptide	epithelia	Microbicidal
RNAase 7	epithelia	Microbicidal
Bacterial/permeability increasing (BPI) protein	neutrophils, epithelia	Microbicidal, lipopolysaccharide binding
Lactoperoxidase	submucosal glands	Conversion of hydrogen peroxide to microcidal halide
Duox (Dual functioning oxidase)	epithelia	Formation of hydrogen peroxide
Clara cell specific 10 kD protein (CC10) (secretoglobin, uetroglobin)	Clara cells	Immunomodulation
Palate, lung, and nasal epithelium (PLUNC)	epithelia	Microbicidal, LPS binding, function not fully understood
Lipocalin; neutrophil gelatinase-associated lipocalin (NGAL)	epithelia	Siderophore binding, function not fully understood

Table 2. Innate immune features of the respiratory tract of infants/neonates and responses to respiratory syncytial virus (RSV).

<u>Innate Immune component</u>	<u>Feature in infants/neonates</u>	<u>Reference</u>
Mucin production	Epithelial and goblet cells and submucosal glands differentiate progressively with respiratory tract development; TLR7, IL-17, IL-23 regulate mucin production in response to RSV infection	57, 85, 89
Ciliary beat frequency	Differences between neonates and adults not fully known	
Dual functioning oxidases and lactoperoxidase	Slight increased activity at 3 weeks of age compared to newborn lung	Manuscript in preparation
Surfactant proteins A and D	Polymorphism associated with severe disease in infants; Differential expression by preterm and term lung with RSV infection; Reduced in infants with severe RSV; Increased production with development	3, 61, 62, 91, 133
Defensins, cathelicidins. antimicrobial peptides, antimicrobial proteins (PLUNC, lipocalin)	Differential expression by preterm and term lung with RSV infection; Increased production by epithelia with development	52, 61, 90, 118, 133
Clara cell CC10 production	Increases with development	9, 10, 108, Figure 2
Type II cell formation	Increased differentiation with pulmonary development	16, 89, 139
Proteoglycans and glycosaminoglycans of the extracellular matrix	Sequester chemokines, cytokines, and growth factors in a latent form that can be released with enzymatic	42

	digestion	
Toll-like receptor (TLR) expression	TLR 4 polymorphisms associated with severe disease in infants; Increased expression of TLR 3, 4 7 and 8 differentially expressed with development	7, 91, 109, 116, 133
Retinoic acid-inducible gene I (RIG-I)	Differences in expression between neonates and adults is not fully known. RIG-I is triggered by RSV infection	
Interferon α and β	Reduced expression/activity mediated by the RSV proteins NS1 and NS2	123, 135
Interferon- γ	IFN- γ is low in secretions of infants and enhances activity of immature alveolar macrophage and RSV clearance	31, 127
Interleukin-1	High IL-1 and low RANTES are associated with more severe clinical scores in infants; IL-1 β levels are associated with severe disease in infants	53, 84, 88
Tumor necrosis factor α	Increased TNF α in infants with severe RSV bronchiolitis and in preterm lambs	88, 131
Interleukin-8	Increased with disease severity in infants; not detected in preterm infants in one study	14, 73
Interleukin-10	Increased with RSV infection in infants	94
Transforming growth factor- β	Inhibits CD4+ cell proliferation and	132

	differentiation in infants	
Macrophage inflammatory protein-1 α	Increased in infants and lambs with bronchiolitis	41, 131
Regulated on Activation Normal T cells Expressed and Secreted (RANTES)	RANTES polymorphisms associated with severe RSV disease; High IL-1 and low RANTES associated with more severe clinical scores	1, 50, 53, 103
CCL2, CCL3, CCL5 CXCL10	Increased chemokine expression with severe RSV bronchiolitis	87
Interleukin-17	IL-17 increased with RSV convalescence; IL-17 mediates mucin production; IL-17 contributes to RSV pathology in vaccine-enhanced model	24, 33, 87
Interleukin-21	IL-21 has little effect on primary RSV infection but reduces RSV disease severity in vaccine-induced enhanced disease model	24, 46
Neutrophils	Neonates have reduced proliferation pool, chemotactic responses, rolling, transmigration, lamellopodia, oxidate activity, lactoferrin and myeloperoxidase	2, 79, 80, 110
Monocytes	Reduced cytokine responses; IFN gamma enhances RSV clearance	31, 66, 79
Dendritic cells	Reduced numbers of DCs in neonates and reduced plasmacytoid DC to myeloid DCs in neonates compared to adults, altered cytokine profiles, reduced antigen expression and maturation;	34-36, 115, 138, 142

	neonatal DC favor Th2 shift	
--	-----------------------------	--

Fig. 1. Schematic illustration depicting some of the innate immune systems of the lung airways and alveoli. (This image was drawn by Ackermann and published in: Ackermann MR, Derscheid RM, Roth JA. VCNA 26:215-228, 2010)




Fig. 2. Expression of CC10 in lung of lambs during ontogeny. CC10 mRNA levels in preterm lung are very low in fetal lung and increase progressively with age (manuscript in preparation). Susceptibility to RSV is increased in preterm infants (and lambs) and reduces expression of innate immune products, such as CC10 may underlie the increased susceptibility to RSV infection. For each timepoint, n = 4 lambs/group and RNA levels were determined by RT-qPCR using 0.784 ng RNA/μl per sample and assessing levels to a Stock I-derived standard curve for CC10 and results were normalized to total lung RNA loaded RT-qPCR. Results were assessed by GraphPad Prism 6 with a one-way ANOVA followed by Tukey's post-test.




Fig. 3. Lung, calf. Pulmonary alveolar macrophages (brown, stained with CD68) within alveolar lumens where they are positioned well for responsiveness to stimuli entering the alveolar lumen. Alveolar blood vessels are congested but along the endothelial area are small regions of staining which may be due to pulmonary intravascular macrophages. Immunohistochemistry stain to CD68 antigen (Dako, primary antibody); Hematoxylin counterstain. 40X. (This image is from Ackermann and published in: Ackermann, et al Vet Pathol 31:340-348, 1994).

